Laura Faravelli

VP Business Development at Newron Pharmaceuticals

Speaker

Laura Faravelli is a Business Development professional with over 20 years of experience in the research, development, and regulatory approval of CNS therapies. She was appointed Vice President of Business Development at Newron Pharmaceuticals in July 2023.

Laura began her career at Pharmacia & Upjohn in 1996 and joined Newron Pharmaceuticals in 2001 as a neurobiologist. She has played a key role in the development of proprietary drugs including safinamide for Parkinson’s disease, ralfinamide for neuropathic pain, and the innovative drug evenamide for schizophrenia.

Laura played a significant role in Newron’s achievement of Xadago®'s marketing authorization from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA).

Laura holds a PhD in Neurobiology and an educational background in Regulatory Affairs and Market Access, combining scientific knowledge with strategic business insight.

As VP of Business Development, Laura has been instrumental in securing strategic licensing deals and partnerships, driving the development of evenamide, and supporting its advancement through critical stages. These initiatives have positioned Newron at the cutting edge of CNS innovation, addressing the evolving challenges in neurology while opening up new strategic opportunities for growth.